Idogen AB (publ)
Save
12.79M
Market cap
–
Current P/E
–
Forward P/E
About
Health care
Sector
Biotechnology
Industry
Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs, and the body's own cells or tissues in Sweden. The company's advanced product candidate is IDO 8 that is designed for patients with severe haemophilia A, who have developed neutralizing antibodies against critical treatment with coagulation factor VIII. It also develops IDO T, a tolerogenic cell therapy to prevent organ transplant rejection primarily kidney transplantation; and IDO AID for the treatment of autoimmune diseases.
Similar securities
Based on sector and market capitalization
Report issue